Business Description
Viking Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US92686J1060
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 815.39 | |||||
Equity-to-Asset | 0.97 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -22.2 | |||||
3-Year EPS without NRI Growth Rate | -18.9 | |||||
3-Year FCF Growth Rate | -37.4 | |||||
3-Year Book Growth Rate | 1.4 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 81.16 | |||||
9-Day RSI | 64.76 | |||||
14-Day RSI | 58.75 | |||||
6-1 Month Momentum % | 736.32 | |||||
12-1 Month Momentum % | 313.45 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 29.48 | |||||
Quick Ratio | 29.48 | |||||
Cash Ratio | 29.38 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -11 | |||||
Shareholder Yield % | -7.86 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -21.59 | |||||
ROA % | -20.64 | |||||
ROIC % | -7011.83 | |||||
ROC (Joel Greenblatt) % | -9535.02 | |||||
ROCE % | -26.28 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 8.77 | |||||
Price-to-Tangible-Book | 8.77 | |||||
EV-to-EBIT | -57.98 | |||||
EV-to-Forward-EBIT | -57.17 | |||||
EV-to-EBITDA | -58.13 | |||||
EV-to-Forward-EBITDA | -57.17 | |||||
EV-to-FCF | -120.86 | |||||
Price-to-Projected-FCF | 20.19 | |||||
Price-to-Net-Current-Asset-Value | 8.78 | |||||
Price-to-Net-Cash | 8.81 | |||||
Earnings Yield (Greenblatt) % | -1.72 | |||||
FCF Yield % | -0.67 |